March 17, 2021
WATERTOWN, Mass., March 17th, 2021 — PlateletBio, a pioneering biotechnology company developingnext-generation allogeneic cell therapies for the treatment of human diseases,has named Hidde Ploegh, PhD, to its Scientific Advisory Board. Dr. Ploegh is abiochemist by training and one of the world’s foremost experts on the immunesystem. He is known for his analysis of the pathways involved in antigenpresentation by products of the Major Histocompatibility Complex (MHC). PlateletBiois developing a next-generation pipeline of cell therapies for autoimmunediseases and Dr. Ploegh’s expertise will accelerate the company’s path todelivering therapeutic benefit to patients.
Dr. Ploegh has spent more than 10years at the MIT's Whitehead Institute for Biomedical Research and is currentlyat Boston Children’s Hospital in their Program in Cellular and MolecularMedicine. Ploegh is a correspondent of the Royal Dutch Academy of Sciences, amember of EMBO, a fellow of the American Academy of Arts and Sciences, and amember of the National Academy of Sciences.
Inspired by the function and versatility of platelets,PlateletBio is pioneering the next generation of safer, more effective allogeneiccell therapy products. Its cell therapy platform produces “platelet-like cells”(PLCs) capable of performing vital biological functions and able to be geneticallyengineered into multiple allogeneic therapies. The company, based in Watertown,Mass., is focused on advancing a diverse pipeline of next-generation cellulartherapies for applications in autoimmune diseases, hematology, oncology, and inflammation.Visit www.plateletbio.com for more information.